318 completed, 84 terminated, 57 recruiting, 49 unknown. 597 Phase 2, 133 Phase 1, 63 Phase 3.
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease | Phase 2 | Not yet recruiting | Polaryx Therapeutics, Inc. | 24 | 2026-12-01 | 2026-07-31 |
| A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome Empasiprubart IV, Empasiprubart Placebo IV, Intravenous immunoglobulin (IVIg) - Guillain-Barré Syndrome (GBS) | Phase 2 | Not yet recruiting | argenx | 63 | 2026-12-01 | 2026-10-28 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab co-formulated with rHuPH20 - Relapsing-remitting Multiple Sclerosis | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 25 | 2026-10-30 | 2026-10-14 |
| A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis PRO-1562 Oral Capsules, Placebo Oral Capsule - Multiple Sclerosis | Phase 1 / Phase 2 | Recruiting | Progentos Therapeutics | 160 | 2026-10-01 | 2026-09-29 |
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-10-30 |
| Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis SYS6020 injection - Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Tongji Hospital | 25 | 2026-09-16 | 2026-08-10 |
| Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Demyelinating Diseases, Demyelination; Corpus Callosum | Phase 1 / Phase 2 | Not yet recruiting | University of California, San Francisco | 44 | 2026-09-15 | 2026-03-11 |
| Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) Indapamide - Multiple Sclerosis | Phase 2 | Not yet recruiting | Eva M.M. Strijbis | 75 | 2026-09-01 | 2026-08-14 |
| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Not yet recruiting | argenx | 6 | 2026-09-01 | 2026-06-10 |
| Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) Intravenous immunoglobulin (IVIG), Efgartigimod Alfa-Fcab - Guillain-Barré Syndrome | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 110 | 2026-09-01 | 2026-09-18 |
| The HIt HArd and hiT Early in Multiple Sclerosis Trial Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis | Phase 2 | Recruiting | Uppsala University | 60 | 2026-09-01 | 2026-10-22 |
| Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-08-30 | 2026-09-09 |
| A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis Terfenadine, Standard First-line Disease-Modifying Therapy - Relapsing Remitting Multiple Sclerosis | Phase 2 | Recruiting | Chuan Qin | 100 | 2026-08-15 | 2026-09-18 |
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
Showing 20 of 597. Sign in to see all of them.
Multiple Sclerosis (383) · Multiple Sclerosis, Relapsing-Remitting (119) · Multiple Sclerosis, Chronic Progressive (75) · Neuromyelitis Optica (39) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (28) · Autoimmune Diseases (21) · Fatigue (20) · Leukodystrophy, Metachromatic (19) · Adrenoleukodystrophy (18) · Muscle Spasticity (15) · Optic Neuritis (13) · Recurrence (12) · Leukodystrophy, Globoid Cell (11) · Guillain-Barre Syndrome (10)
Nervous System Diseases (589) · Immune System Diseases (551) · Autoimmune Diseases of the Nervous System (540) · Autoimmune Diseases (528) · Demyelinating Autoimmune Diseases, CNS (510) · Pathological Conditions, Signs and Symptoms (194) · Pathologic Processes (143) · Disease Attributes (133) · Chronic Disease (117) · Multiple Sclerosis (91) · Central Nervous System Diseases (71) · Brain Diseases (61) · Eye Diseases (55) · Signs and Symptoms (55)
Interferon beta-1a (20) · Rituximab (17) · 4-Aminopyridine (12) · Methylprednisolone (12) · Cyclophosphamide (10) · Glatiramer Acetate (9) · Interferon beta-1b (9) · Alemtuzumab (8) · Immunoglobulins, Intravenous (8) · Natalizumab (8) · Dimethyl Fumarate (7) · ocrelizumab (7) · teriflunomide (7) · Metformin (6) · Prednisone (6)
Biogen (20) · National Institute of Neurological Disorders and Stroke (NINDS) (14) · Novartis Pharmaceuticals (11) · Sanofi (10) · Tianjin Medical University General Hospital (10) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Johns Hopkins University (8) · Oregon Health and Science University (8) · University of Calgary (8) · GlaxoSmithKline (7) · S. Andrea Hospital (7) · University of California, Los Angeles (7) · University of California, San Francisco (7) · VA Office of Research and Development (7) · Charite University, Berlin, Germany (6)
United States (267) · Germany (89) · Canada (83) · Spain (75) · United Kingdom (74) · Italy (62) · Poland (61) · France (53) · Russia (46) · Czechia (43) · Denmark (32) · Ukraine (32) · Belgium (31) · China (30) · Netherlands (30)
Michael Levy, MD, PhD (5) · Paul Orchard, MD (5) · Richard Burt, MD (5) · Bibiana Bielekova, M.D. (4) · Albert Lo, MD PhD (3) · Arnon Karni, MD (3)
PMID 31072380, PMID 21586746, PMID 12542793, PMID 15864738, PMID 20937945, PMID 22622860, PMID 23982748, PMID 24759263, PMID 25442786, PMID 25546364, PMID 27411694, PMID 27574516, PMID 28129749, PMID 28607708, PMID 33023488, PMID 33253391, PMID 33332761, PMID 34135843, PMID 34240656, PMID 35078125, PMID 36163349, PMID 36196048, PMID 37715710, PMID 38729747, PMID 40267426, PMID 11231629, PMID 11386586, PMID 11399225, PMID 12064356, PMID 12084892, PMID 15703014, PMID 15784740, PMID 16002461, PMID 16194720, PMID 16567708, PMID 16908728, PMID 16971719, PMID 17058754, PMID 17502467, PMID 18272891, PMID 18398457, PMID 18507817, PMID 18565456, PMID 18572078, PMID 18645164, PMID 18671877, PMID 18703004, PMID 18946064, PMID 18952896, PMID 18970976
2014 (7), 2023 (7), 2009 (6), 2018 (5), 2025 (5), 2005 (4), 2008 (4), 2019 (4), 2016 (3), 2017 (2), P50AT000066 (2), 1IK2RX001180-01A2 (1), 2004 (1), 2015 (1), K23AT002155 (1)